Diflunisal versus naproxen in the management of rheumatoid arthritis

Thomas Osborn, R. L. Parks, T. L. Moore, M. W. Grisanti, G. Nesher, B. A. Caciolo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Diflunisal (500 mg orally, twice daily) and naproxen (375 mg orally, twice daily) were compared for efficacy and tolerability in a 12-week open-label study in 33 patients with active rheumatoid arthritis (RA). Both drugs resulted in marked reduction in the number of swollen, tender, and painful joints and comparable improvement in patients' assessment of disease activity and pain. There were no significant differences between the two medications in the measured indices of disease activity. No adverse experiences were reported by patients in either treatment group. The results indicate that both diflunisal and naproxen were equally effective and that both agents are generally well tolerated in this group of patients with RA.

Original languageEnglish (US)
Pages (from-to)736-743
Number of pages8
JournalClinical Therapeutics
Volume11
Issue number6
StatePublished - Dec 1 1989
Externally publishedYes

Fingerprint

Diflunisal
Naproxen
Rheumatoid Arthritis
Joints
Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Osborn, T., Parks, R. L., Moore, T. L., Grisanti, M. W., Nesher, G., & Caciolo, B. A. (1989). Diflunisal versus naproxen in the management of rheumatoid arthritis. Clinical Therapeutics, 11(6), 736-743.

Diflunisal versus naproxen in the management of rheumatoid arthritis. / Osborn, Thomas; Parks, R. L.; Moore, T. L.; Grisanti, M. W.; Nesher, G.; Caciolo, B. A.

In: Clinical Therapeutics, Vol. 11, No. 6, 01.12.1989, p. 736-743.

Research output: Contribution to journalArticle

Osborn, T, Parks, RL, Moore, TL, Grisanti, MW, Nesher, G & Caciolo, BA 1989, 'Diflunisal versus naproxen in the management of rheumatoid arthritis', Clinical Therapeutics, vol. 11, no. 6, pp. 736-743.
Osborn T, Parks RL, Moore TL, Grisanti MW, Nesher G, Caciolo BA. Diflunisal versus naproxen in the management of rheumatoid arthritis. Clinical Therapeutics. 1989 Dec 1;11(6):736-743.
Osborn, Thomas ; Parks, R. L. ; Moore, T. L. ; Grisanti, M. W. ; Nesher, G. ; Caciolo, B. A. / Diflunisal versus naproxen in the management of rheumatoid arthritis. In: Clinical Therapeutics. 1989 ; Vol. 11, No. 6. pp. 736-743.
@article{d3bb5ed08378475587c501e32ce34f67,
title = "Diflunisal versus naproxen in the management of rheumatoid arthritis",
abstract = "Diflunisal (500 mg orally, twice daily) and naproxen (375 mg orally, twice daily) were compared for efficacy and tolerability in a 12-week open-label study in 33 patients with active rheumatoid arthritis (RA). Both drugs resulted in marked reduction in the number of swollen, tender, and painful joints and comparable improvement in patients' assessment of disease activity and pain. There were no significant differences between the two medications in the measured indices of disease activity. No adverse experiences were reported by patients in either treatment group. The results indicate that both diflunisal and naproxen were equally effective and that both agents are generally well tolerated in this group of patients with RA.",
author = "Thomas Osborn and Parks, {R. L.} and Moore, {T. L.} and Grisanti, {M. W.} and G. Nesher and Caciolo, {B. A.}",
year = "1989",
month = "12",
day = "1",
language = "English (US)",
volume = "11",
pages = "736--743",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - Diflunisal versus naproxen in the management of rheumatoid arthritis

AU - Osborn, Thomas

AU - Parks, R. L.

AU - Moore, T. L.

AU - Grisanti, M. W.

AU - Nesher, G.

AU - Caciolo, B. A.

PY - 1989/12/1

Y1 - 1989/12/1

N2 - Diflunisal (500 mg orally, twice daily) and naproxen (375 mg orally, twice daily) were compared for efficacy and tolerability in a 12-week open-label study in 33 patients with active rheumatoid arthritis (RA). Both drugs resulted in marked reduction in the number of swollen, tender, and painful joints and comparable improvement in patients' assessment of disease activity and pain. There were no significant differences between the two medications in the measured indices of disease activity. No adverse experiences were reported by patients in either treatment group. The results indicate that both diflunisal and naproxen were equally effective and that both agents are generally well tolerated in this group of patients with RA.

AB - Diflunisal (500 mg orally, twice daily) and naproxen (375 mg orally, twice daily) were compared for efficacy and tolerability in a 12-week open-label study in 33 patients with active rheumatoid arthritis (RA). Both drugs resulted in marked reduction in the number of swollen, tender, and painful joints and comparable improvement in patients' assessment of disease activity and pain. There were no significant differences between the two medications in the measured indices of disease activity. No adverse experiences were reported by patients in either treatment group. The results indicate that both diflunisal and naproxen were equally effective and that both agents are generally well tolerated in this group of patients with RA.

UR - http://www.scopus.com/inward/record.url?scp=0024792207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024792207&partnerID=8YFLogxK

M3 - Article

C2 - 2692819

AN - SCOPUS:0024792207

VL - 11

SP - 736

EP - 743

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -